Here are four things to know.
1. Osmolex contains both immediate-release and extended-release forms of the drug amantadine, a known treatment for Parkinson’s. Patients take the pill once-daily in the morning.
2. The FDA also approved Osmolex to treat patients with drug-induced movement disorders.
3. The drug’s formulation is protected by three patents valid through March 2030.
4. Osmotica Pharmaceutical said it is finalizing commercialization plans to launch the drug as soon as possible, though the drugmaker did not share an exact date.
More articles on supply chain:
Novartis looks to auction off US generics business: 4 takeaway
AstraZeneca’s immunotherapy drug OK’d for lung cancer: 5 things to know
J&J reportedly seeks buyers for its $2B sterilization division: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
